Review of Optometry - Vision declines in one working eye: dilated veins and blot hemorrhages further confound the diagnosis.(Retina Quiz)(diagnosing ocular ischemia syndrome)
Business Editors/Health & Pharmaceutical Writers
MINNEAPOLIS–(BUSINESS WIRE)–Sept. 22, 2003
Merck & Co., Inc. (NYSE:MRK)
FOSAMAX and Evista Demonstrated Similar Upper GI Safety and Overall
Tolerability Profiles in Two Head-to-Head Studies Presented at ASBMR
In one-year head-to-head trials comparing FOSAMAX(R)(alendronate sodium) once-weekly, the most prescribed medicine(1) for osteoporosis treatment, to Evista, FOSAMAX 70 mg provided significantly greater increases in bone mineral density (BMD) at one-year at the lumbar spine and total hip compared to Evista (raloxifene) 60 mg once-daily. Findings from these two studies, one conducted in the U.S. and one internationally, were presented this week at the 25th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Eight Major Job Trends For 2008
Five Ways To Successfully Negotiate A Salary
Today’s Best Part-Time Jobs
“These studies are important because they are the first to compare weekly alendronate to raloxifene once daily,” said Risa Kagan, M.D., co-medical director, FORE-Foundation for Osteoporosis Research and Education, Oakland, Calif. and a researcher on the study. “Because these medicines work by different mechanisms, clinical studies like these provide doctors with helpful information on efficacy and tolerability, which helps in making treatment decisions for patients.”
Significantly more women responded to treatment with FOSAMAX than with Evista
In both of these studies, after one year of treatment, postmenopausal women taking FOSAMAX experienced a two-fold increase in BMD at the lumbar spine, the primary endpoint, compared to patients receiving Evista (U.S. study: 4.4 percent increase from baseline for FOSAMAX versus 1.9 percent increase for Evista, p
